Results about: breast cancer

<p>Gomis</p>

Intricate signalling networks control cell division, differentiation, movement, organization and death. Understanding how cells read and transform these signals into changes in cell behaviour is a major research focus of our group.

P38MAM

New combination therapy for breast tumours, with selection marker

Mapping tumour development

The scientist Roger Gomis receives funding from the “la Caixa” Foundation for a project devoted to metastatic breast cancer.

Tumour cells evade death through in extremis DNA repair

A study on breast cancer conducted at IRB Barcelona identifies the key role of p38 in safeguarding tumour cells against the excessive accumulation of DNA damage, which would otherwise cause cell death.

p38 blockage has been shown to increase the death of tumour cells, thus causing tumours to shrink.

The combination of p38 inhibitors with chemotherapeutic drugs (taxanes) strengthens, accelerates or prolongs the antitumour effect in patient-derived tumours grown in mice.

An ERC Proof of Concept grant to fight drug resistance in breast cancer

IRB Barcelona scientist, Modesto Orozco has been granted 150,000 euros to optimise and validate a promising anti-tumour therapeutic tool over 18 months.